Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine Maintenance in Advanced Gastric Cancer
NCT01468389Phase 3Unknown
- Sponsor
- 307 Hospital of the People's Liberation Army
- Start
- Nov 2011
- Primary completion
- Jan 2013
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of capecitabine in gastric adenocarcinoma, esophagogastric junction adenocarcinoma (GEJA), sponsored by 307 Hospital of the People's Liberation Army. Status: unknown.
02
Drugs
capecitabine
03
Conditions
gastric adenocarcinomaesophagogastric junction adenocarcinoma (GEJA)
Beyond the preview
Go deeper on NCT01468389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01468389.